Not available
Quote | Transgene S.A. (OTCMKTS:TRGNF)
Last: | $1.59 |
---|---|
Change Percent: | 0.0% |
Open: | $1.59 |
Close: | $1.59 |
High: | $1.59 |
Low: | $1.59 |
Volume: | 700 |
Last Trade Date Time: | 06/06/2024 03:00:00 am |
News | Transgene S.A. (OTCMKTS:TRGNF)
Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a....
TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial vis...
Message Board Posts | Transgene S.A. (OTCMKTS:TRGNF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a....
TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial vis...
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...